A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg

Title
A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg
Author(s)
김영조이철환[이철환]백상홍[백상홍]홍택종[홍택종]최용진[최용진]안태훈[안태훈]임상현[임상현]배장호[배장호]홍순준[홍순준]김두일[김두일]안영근[안영근]허성호[허성호]박대건[박대건]최동주[최동주]이성욱[이성욱]김범수[김범수]류규형[류규형]장양수[장양수]이상훈[이상훈]성기배[성기배]김효수[김효수]
Keywords
CLINICAL-TRIALS; PRIMARY-CARE; GOALS; EFFICACY; SAFETY; GUIDELINES; STATINS
Issue Date
201004
Publisher
SPRINGER
Citation
CARDIOVASCULAR DRUGS AND THERAPY, v.24, no.2, pp.181 - 188
Abstract
This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients. Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n = 29; intermediate risk, n = 45; high risk, n = 351). The starting dose depended on a patient's cardiovascular risk and LDL-cholesterol (LDL-C) levels. Of the patients, 253 (59.5%), 63 (14.8%) and 109 (25.6%) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8%) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9% of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0%). 89.1% of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1% of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40% reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by similar to 10% by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6%). Atorvastatin was well tolerated at all dose levels. Patient-tailored statin therapy according to an individual's risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.
URI
http://hdl.handle.net/YU.REPOSITORY/22598http://dx.doi.org/10.1007/s10557-010-6225-0
ISSN
0920-3206
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE